APPLICATION
ANDA078484
TYPE
ANDA
ORIGINAL APPROVAL
2009-05-27
LATEST ACTION
2023-06-28
ROUTE
ORAL
DOSAGE FORM
CAPSULE, EXTENDED RELEASE
MARKETING STATUS
Discontinued
Products
GALANTAMINE HYDROBROMIDEDiscontinued
GALANTAMINE HYDROBROMIDE EQ 24MG BASE · CAPSULE, EXTENDED RELEASE · ORAL
GALANTAMINE HYDROBROMIDEDiscontinued
GALANTAMINE HYDROBROMIDE EQ 8MG BASE · CAPSULE, EXTENDED RELEASE · ORAL
GALANTAMINE HYDROBROMIDEDiscontinued
GALANTAMINE HYDROBROMIDE EQ 16MG BASE · CAPSULE, EXTENDED RELEASE · ORAL
Approval history
2023-06-28Labeling · Supplement 11 · standardAP
2023-06-28Labeling · Supplement 10 · standardAP
2019-12-06Labeling · Supplement 8 · standardAP
2009-05-27OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.